|8.60||-0.0200||-0.23%||Vol 97.51K||1Y Perf -11.68%|
|Nov 30th, 2023 16:00 DELAYED|
|- -||0.13 1.51%|
|Target Price||15.67||Analyst Rating||Strong Buy 1.00|
|Potential %||82.21||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★ 41.66|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||50.55||Earnings Rating||Strong Sell|
|Market Cap||228.47M||Earnings Date||6th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.11|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||58.19K|
|Avg. Monthly Volume||79.31K|
|Avg. Quarterly Volume||72.26K|
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) stock closed at 8.6 per share at the end of the most recent trading day (a -0.23% change compared to the prior day closing price) with a volume of 97.51K shares and market capitalization of 228.47M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. Fennec Pharmaceuticals Inc. CEO is Rostislav Raykov.
The one-year performance of Fennec Pharmaceuticals Inc. stock is -11.68%, while year-to-date (YTD) performance is -10.42%. FENC stock has a five-year performance of 28.36%. Its 52-week range is between 6.3 and 10.85, which gives FENC stock a 52-week price range ratio of 50.55%
Fennec Pharmaceuticals Inc. currently has a PE ratio of -12.50, a price-to-book (PB) ratio of 91.91, a price-to-sale (PS) ratio of 660.88, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -81.15%, a ROC of -81.74% and a ROE of -225.12%. The company’s profit margin is -%, its EBITDA margin is -9 566.50%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Fennec Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. Fennec Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Fennec Pharmaceuticals Inc. is Strong Buy (1), with a target price of $15.67, which is +82.21% compared to the current price. The earnings rating for Fennec Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Fennec Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Fennec Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.04, ATR14 : 0.42, CCI20 : 79.26, Chaikin Money Flow : 0.02, MACD : 0.38, Money Flow Index : 77.91, ROC : 13.46, RSI : 63.15, STOCH (14,3) : 81.45, STOCH RSI : 0.23, UO : 50.95, Williams %R : -18.55), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Fennec Pharmaceuticals Inc. in the last 12-months were: Andrade Robert (Option Exercise at a value of $61 250), Andrade Robert (Sold 25 000 shares of value $223 325 ), Chris A. Rallis (Option Excercise at a value of $14 996), RALLIS CHRIS A (Option Exercise at a value of $5 069), RALLIS CHRIS A (Sold 2 207 shares of value $18 693 )
Thu, 05 Oct 2023 13:06 GMT Fennec Pharmaceuticals (FENC) Receives a Buy from Craig-Hallum- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.